Non-receptor tyrosine kinase

Results: 28



#Item
21Lung Cancer, EGFR with ALK reflex, Tumor Algorithm  Clinical diagnosis of non-small-cell lung cancer. Order: EGFRX / Lung Cancer, EGFR with ALK reflex, Tumor

Lung Cancer, EGFR with ALK reflex, Tumor Algorithm Clinical diagnosis of non-small-cell lung cancer. Order: EGFRX / Lung Cancer, EGFR with ALK reflex, Tumor

Add to Reading List

Source URL: www.mayomedicallaboratories.com

Language: English - Date: 2014-08-08 15:15:55
22Abstract # 1048  Phase I study of HM61713, a novel epidermal growth factor receptor (EGFR) mutant selective inhibitor, in non-small cell lung cancer (NSCLC) patients having an activating EGFR mutation but failed to prior

Abstract # 1048 Phase I study of HM61713, a novel epidermal growth factor receptor (EGFR) mutant selective inhibitor, in non-small cell lung cancer (NSCLC) patients having an activating EGFR mutation but failed to prior

Add to Reading List

Source URL: www.hanmipharm.com

Language: English - Date: 2014-03-27 02:03:41
23Abstract # 2029  Phase I study of HM781-36B, an irreversible pan-HER tyrosine kinase inhibitor (TKI) in patients with advanced solid tumor and the therapeutic potential in patients with advanced non-small cell lung cance

Abstract # 2029 Phase I study of HM781-36B, an irreversible pan-HER tyrosine kinase inhibitor (TKI) in patients with advanced solid tumor and the therapeutic potential in patients with advanced non-small cell lung cance

Add to Reading List

Source URL: www.hanmipharm.com

Language: English - Date: 2014-03-27 02:03:42
24High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer

High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer

Add to Reading List

Source URL: medicalxpress.com

Language: English - Date: 2014-11-28 04:57:51
25Alethia Biotherapeutics Announces the Filing of a US Provisional Patent Application Covering New Treatment Methods for its EMT Inhibitor AB-16B5 MONTREAL, March 9, 2012 – Alethia Biotherapeutics Inc., a privately held

Alethia Biotherapeutics Announces the Filing of a US Provisional Patent Application Covering New Treatment Methods for its EMT Inhibitor AB-16B5 MONTREAL, March 9, 2012 – Alethia Biotherapeutics Inc., a privately held

Add to Reading List

Source URL: alethiabio.com

Language: English - Date: 2013-01-13 13:00:48
26AstraZeneca  AZD9291 Mechanism of Action

AstraZeneca AZD9291 Mechanism of Action

Add to Reading List

Source URL: www.ncats.nih.gov

Language: English - Date: 2014-05-12 12:58:35
27Press Release  Daiichi Sankyo Europe GmbH Zielstattstrasse[removed]Munich · Germany Phone +[removed]

Press Release Daiichi Sankyo Europe GmbH Zielstattstrasse[removed]Munich · Germany Phone +[removed]

Add to Reading List

Source URL: www.daiichi-sankyo.eu

Language: English - Date: 2014-06-28 10:54:48
28Carriage of methicillin-resistant Staphylococcus pseudintermedius in dogs--a longitudinal study

Carriage of methicillin-resistant Staphylococcus pseudintermedius in dogs--a longitudinal study

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Language: English